Freestyle Libre glucose sensors were added to the drug tariff mid-year in 2017-18, without advance notice or additional funding. The cost of providing these devices to diabetic patients was significant.
Thames Valley CCGs asked SCW to support them to develop a consistent regional commissioning policy. This was a sensitive project with high public interest and involvement from diabetes charities and advocacy groups. Managing patient expectations throughout the process for adoption of items into local prescribing formularies was challenging.
SCW reviewed evidence and guidance, conducted an impact assessment and consulted local specialists, prior to drafting a commissioning policy.
Heather Motion, SCW’s Medicines Optimisation Lead, worked with adult and paediatric specialists in primary and secondary care to manage the introduction of provision of the device in Oxfordshire. Patient needs were reviewed to ensure that the policy for the provision of the device was based on criteria that would ensure that those most likely to benefit were prioritised.
“I just wanted to send a quick email to recognise the excellent work you and the Meds Management team have done around the issue of Freestyle Libre. At regional meetings Oxfordshire has been held up as a beacon of good practice for developing a coherent and practical approach - in other areas there is significant fall-out over the issue.”
Amar Latif, OCCG Clinical Lead for Long Term Conditions